RG
AUPH icon

Redmile Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Redmile Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-323,265
Closed -$2.1M – 86
2019
Q1 		$2.1M Buy
+323,265
New +$2.14M 0.06% 65
2017
Q4 		– Sell
-332,310
Closed -$2.08M – 72
2017
Q3 		$2.08M Hold
332,310
– – 0.1% 57
2017
Q2 		$2.04M Buy
332,310
+192,067
+137% +$1.29M 0.12% 55
2017
Q1 		$1.03M Buy
140,243
+103,500
+282% +$478K 0.07% 56
2016
Q4 		$77K Sell
36,743
-150,867
-80% -$485K 0.01% 48
2016
Q3 		$565K Buy
187,610
+159,200
+560% +$429K 0.04% 43
2016
Q2 		$79K Buy
28,410
+8,700
+44% +$23.8K 0.01% 52
2016
Q1 		$58K Buy
19,710
+3,100
+19% +$7.5K 0.01% 46
2015
Q4 		$41K Buy
+16,610
New +$45.1K ﹤0.01% 57

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group's AUPH Position: Q2 2019 in Review

Redmile Group sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2019, closing a stake of 323,265 shares — an estimated $2.1M sold.

Redmile Group first reported a position in AUPH in Q4 2015 and held it in 9 quarters. The position peaked at $2.1M in Q1 2019. 73 funds tracked by Wall St. Rank hold AUPH as of Q2 2019.

  • Redmile Group reported no remaining Aurinia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Redmile Group sold 323,265 Aurinia Pharmaceuticals shares in Q2 2019, an estimated $2.1M.
  • Redmile Group first reported a position in Aurinia Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Redmile Group's Aurinia Pharmaceuticals position peaked at $2.1M in Q1 2019.
  • 73 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2019.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.